Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Single Arm Phase II Clinical Study Evaluating the Efficacy and Safety of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

NCT05331326 is registered in ClinicalTrials.gov with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT05331326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05331326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Single Arm Phase II Clinical Study Evaluating the Efficacy and Safety of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
Lead sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2022
Completion date
August 31, 2024
Enrollment
64 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer